奥利司他对肥胖伴非酒精性脂肪性肝病的作用及危险因素的影响

The Analysis of The efficacy and risk factors in obesity with non-alcoholic fatty liver disease subjects treated with orlistat.

探讨奥利司他(orlistat)在治疗肥胖伴非酒精性脂肪性肝病(NAFLD)中的作用。选择体重指数(BM I)在25和32之间,伴有肝功能异常的NAFLD患者30例,给予奥利司他120mg,日三次口服,治疗24周。治疗结束后,所有患者的体重、BM I、腰围、腰臀比及血压明显下降(P值均<0.001);肝功能中ALT、AST、GGT、Tch、TG及IR与治疗前相比有明显改善(P值均<0.001);肝脏CT密度值及肝/脾CT密度比值均显著增加(P值均<0.001)。奥利司他可有效地减少NAFLD患者肝脏内脂肪沉积,改善肝功能和相关代谢综合征,可作为肥胖伴NAFLD的药物治疗选择。

To evaluate the efficacy of odistat in the treatment of obesity with non -alcoholic fatty liver disease. Odistat 120mg, three times per day for a couse of 24 weeks, were given to the 30 cases non - alcoholic fatty liver disease （NAFLD） patients whose body mass index （BMI） were between 25 and 32. After 24 weeks treatment, mean weight,BMI, waist and waist/hip ratio（WHR） and blood pressure was significantly decreased （ P 〈 0. 001 ） ; Liver functions （ ALT ,AST, GGT,TG and Tch） and IR was significantly decreased （P 〈 0. 001 ） ;The liver density value by CT scan and liver/spleen ratio by CT scan was significantly increased （ P 〈0. 001 ）. Orlistat can decrease the fat deposit on liver of NAFLD, improve the liver function and metabolic syndrome. It is a drug choice for obese patients with NAFLD.